| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 60 | 26,030 | 0 | 0 | 0 |
| Sales Growth | -99.77% | unch | unch | unch | unch |
| Net Income | -55,480 | -15,630 | -59,500 | -114,440 | -204,970 |
| Net Income Growth | -254.96% | +73.73% | +48.01% | +44.17% | -71.64% |
Connect Biopharma Holdings Ltd ADR (CNTB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. The company's product candidate includes CBP-201. Connect Biopharma Holdings Limited is based in TAICANG, China.
Fiscal Year End Date: 12/31